Author:
Gorelyshev Sergey,Valiakhmetova Endzhe,Pronin Igor
Publisher
Springer International Publishing
Reference95 articles.
1. Ammoun S, Hanemann CO (2011) Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 7(7):392–399
2. Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncol 13(7):759–766
3. Asthagiri A, Parry D, Butman J, Kim H, Tsilou E, Zhuang Z et al (2009) Neurofibromatosis type 2. Lancet 373:1974–1986
4. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A, Canada AB (2007) Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro-Oncol 9(4):447–453
5. Barbi G, Rossier E, Vossbeck S, Hummler H, Lang D, Flock F, … Kehrer-Sawatzki H (2002) Constitutional de novo interstitial deletion of 8 Mb on chromosome 22q12.1–12.3 encompassing the neurofibromatosis type 2 (NF-2) locus in a dysmorphic girl with severe malformations. Med Genet 36:1–4